<DOC>
	<DOCNO>NCT00074191</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , methotrexate , procarbazine , lomustine , dexamethasone , cytarabine , use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treat patient primary CNS lymphoma .</brief_summary>
	<brief_title>Methotrexate , Procarbazine , Lomustine , Dexamethasone , Cytarabine Treating Patients With Primary CNS Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine toxicity efficacy methotrexate , procarbazine , lomustine , dexamethasone , cytarabine patient primary CNS lymphoma . Secondary - Determine ability recruit adequate number patient study . - Compare progression-free dementia-free survival standard measure overall survival , progression-free survival , disease-free survival , complete response rate , cognitive function , quality life patient treat regimen . - Determine feasibility conduct future phase III study treatment regimen patient . - Correlate neuropsychological outcome neuroimaging ( MRI ) outcomes patient treated regimen . OUTLINE : This nonrandomized , multicenter study . - Induction chemotherapy : Patients receive methotrexate IV 3 hour day 1 , 10 , 20 intraventricularly intrathecally ( IT ) 5 minute day 1 , 5 , 10 , 15 ; oral procarbazine day 1-7 ; oral lomustine day 1 ; oral dexamethasone every 6 hour day 1-14 followed taper ( tolerate ) ; cytarabine intraventricularly IT 5 minute day 1 , 5 , 10 , 15 . Treatment repeat every 42 day total 3 course . Patients intraocular lymphoma also receive methotrexate intravitreally twice weekly vitreous clear cell slit lamp exam . Patients stable respond disease proceed maintenance therapy . - Maintenance chemotherapy : Patients receive methotrexate IV 3 hour IT 5 minute day 1 ; oral procarbazine day 1-7 ; oral lomustine day 1 ; oral dexamethasone every 6 hour day 1-14 followed taper ( tolerate ) ; cytarabine intraventricularly IT 5 minute day 1 . Treatment repeat every 42 day total 5 course . Patients intraocular lymphoma also receive methotrexate intravitreally weekly 1 month monthly 1 year . Quality life assess baseline , 6 month , completion treatment , every 6 month 2 year , annually thereafter . Patients follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 180 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm intermediate highgrade primary CNS lymphoma document brain biopsy cerebrospinal fluid vitrectomy analysis Diagnosed within past 90 day No systemic lymphoma NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age 16 75 Performance status ECOG 03 OR Karnofsky 40100 % Life expectancy Not specify Hematopoietic WBC least 2,500/mm^3 Hematocrit least 25 % ( transfusion allow ) Absolute granulocyte count least 1,200/mm^3 Platelet count least 100,000/mm^3 OR least low limit normal ( transfusion independent ) Hepatic Bilirubin great 2.0 time upper limit normal Renal Creatinine clearance least 30 mL/min Cardiovascular Adequate cardiac function tolerate general anesthesia Pulmonary Adequate pulmonary function tolerate general anesthesia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study participation No uncontrolled , clinically significant confound medical condition within past 30 day No know allergy study agent HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 4 week since prior chemotherapy ( 6 week nitrosoureas ) Singleagent methotrexate administer within past 14 day allow Endocrine therapy Not specify Radiotherapy No prior cranial spinal radiotherapy Surgery Prior surgery biopsy allow</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system lymphoma</keyword>
</DOC>